Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for KAE609

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug KAE609?

KAE609 is an investigational drug.

There have been 7 clinical trials for KAE609. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1^st 2013.

The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, Wellcome Trust, and Medicine for Malaria Venture.

Summary for KAE609

US Patents	0
International Patents	0
US Patent Applications	13
WIPO Patent Applications	7
Japanese Patent Applications	4
Clinical Trial Progress	Phase 2 (2013-07-01)
Vendors	27

Recent Clinical Trials for KAE609

Title	Sponsor	Phase
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria	EDCTP within the PAMAFRICA Grant	Phase 2
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria	European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase 2
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria	Wellcome Trust	Phase 2

See all KAE609 clinical trials

Clinical Trial Summary for KAE609

Top disease conditions for KAE609

Top clinical trial sponsors for KAE609

See all KAE609 clinical trials

US Patents for KAE609

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Baxter

Moodys

Mallinckrodt

Dow

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.